Drugs / Allergovit 6-grasses
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02297490 | Jan → Nov 2014 | allergic disease | Allergopharma GmbH & Co. KG | Terminated | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00263601 | Nov 2001 → May 2004 | seasonal allergic rhinitis | Allergopharma GmbH & Co. KG | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allergovit 6-grasses | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00263601 ↗ |
| Known as | Allergovit | “an additional short course of specific immunotherapy with the high-dose, hypoallergenic grass pollen preparation Allergovit was performed in 61 patients of the active treatment...” PMID 17523386 ↗ Apr 2007 |
| Modality | Protein / enzyme biologic | “grass pollen allergoid adsorbed to aluminium hydroxide” PMID 15876311 ↗ Jun 2005 |
| Route | Subcutaneous | “Subcutaneous injections” NCT00263601 ↗ |